03/06/2026
Retatrutide Alert Post
I am getting lots of requests for advice regarding Retatrutide. So here it is.
Retatrutide is a drug still under study. X2 major Phase 3 trials are yet to be concluded. Studies are important to gauge health benefits, side effects and potentially serious detrimental health effects. The striking irony is that when these studies where rushed through, but non the less completed for Covid vaccination due to the urgency of the pandemic, plenty of people where sceptical to take the vaccine. Now this injectable that has not completed the most important studies is doing the rounds, and plenty of people are all too happy to gamble with their health.
Also, Retatrutide being sold at the moment is black market produce. We have no assurances of quality control over the production, and transportation of the Retarutide before it arrives at the end consumer.
I understand peoples wish to control certain health conditions. But in light of the fact that we do have present, studied, approved medications vs an unknown, I cannot understand the need of people to seek the use of this experimental drug.
For all I know Retatrutide can be approved tomorrow, with foreseeable outcomes and an idea of the risk vs benefit profile. And we will be able to assess and balance the potential benefits, vs the condition of the patient. But till then, it is impossible for any doctor in their right senses to recommend it.
Take care.
Post ta' Twissija dwar ir-Retatrutide
Qed nirċievi ħafna talbiet għal pariri dwar ir-Retatrutide, għalhekk hawn l-opinjoni tiegħi.
Ir-Retatrutide hija mediċina li għadha qed tiġi studjata. Għad fadal żewġ studji ewlenin tal-Fażi 3 biex jiġu konklużi. L-istudji huma importanti biex jevalwaw il-benefiċċji għas-saħħa, l-effetti sekondarji u anke effetti potenzjalment serji u ta' ħsara għas-saħħa.
L-ironija kbira hija li meta l-istudji tal-vaċċini tal-Covid ġew mgħaġġla minħabba l-urġenza tal-pandemija, iżda xorta waħda tlestew qabel l-approvazzjoni, ħafna nies kienu xettiċi biex jieħdu l-vaċċin. Issa din l-injezzjoni, li għadha ma lestietx l-aktar studji importanti tagħha, qed tiċċirkola sew u ħafna nies jidhru lesti li jirriskjaw saħħithom billi jużawha.
Barra minn hekk, ir-Retatrutide li qed tinbiegħ bħalissa hija prodott tas-suq iswed. M'għandna l-ebda garanzija dwar il-kontroll tal-kwalità fil-produzzjoni tagħha, jew dwar kif ġiet maħżuna u ttrasportata qabel waslet għand il-konsumatur.
Nifhem ix-xewqa tan-nies li jikkontrollaw ċerti kundizzjonijiet tas-saħħa. Iżda fid-dawl tal-fatt li bħalissa għandna mediċini studjati, approvati u disponibbli, ma nistax nifhem għaliex xi nies qed ifittxu li jużaw din il-mediċina sperimentali.
Jista' jkun li għada r-Retatrutide tiġi approvata, b'informazzjoni ċara dwar l-effetti tagħha u b'idea aktar preċiża tal-bilanċ bejn ir-riskji u l-benefiċċji. F'dak il-punt inkunu nistgħu nivvalutaw dawn il-benefiċċji potenzjali fil-kuntest tal-kundizzjoni tal-pazjent.
Iżda sa dak iż-żmien, huwa impossibbli għal kwalunkwe tabib responsabbli u b'ġudizzju kliniku tajjeb li jirrakkomanda l-użu tagħha.
Ħudu ħsieb.
